Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
Alnylam & Regeneron's siRNA therapy brezosiran reduced mutant huntingtin protein 60-64% in 9 patients, spurring plans for a ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Roche’s Teresa Graham says patients are clamoring for breast cancer pill giredestrant as two US approval decisions near.
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
FDA weighs evidence standards for AI medical devices like prescription bots. AMA opposes upfront uncertainty; ATA Action supports post-market monitoring. UpDoc, AMA, and others back risk-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results